Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by SciSparc Ltd
< Previous
1
2
Next >
New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder
November 24, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel
November 22, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation
November 15, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication
November 10, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology
October 31, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
October 24, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
October 16, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
October 13, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
October 11, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Granted European Patent for its Core Technology
October 03, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
September 29, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
September 27, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces 1-for-26 Reverse Share Split
September 20, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
September 12, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
September 07, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
September 07, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering
August 14, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
August 10, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million
August 09, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
August 01, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
July 14, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
June 30, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
June 21, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
June 16, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals
June 07, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
June 02, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP
May 30, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Developed its Core Algorithm to allow suitable Modelling of Human Mitochondrial Carriers for Accelerating its Cancer Drug Discovery Program
May 08, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation
May 02, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
SPRC
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
April 21, 2023
From
SciSparc Ltd
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright